Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy's Laboratories Announces the Launch of Vigabatrin Tablets, USP in the U.S. Market
Details : The launch of Vigabatrin Tablets USP, 500 mg, which is therapeutic equivalent generic version of Sabril® (vigabatrin) Tablets, USP, is approved by the U.S. Food and Drug Administration (USFDA).
Product Name : Vigabatrin-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 02, 2021
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Granules India Limited announces approval of Vigabatrin for Oral Solution USP, 500 mg
Details : Generic version of vigabatrin is approved as monotherapy for pediatric patients with refractory complex partial seizures or infantile spasms 1 month to 2 years of age.
Product Name : Sabril-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2020
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Bora Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Bora Expands Rare Disease Portfolio with Pyros Pharma Acquisition
Details : Through the acquisition of US-based Pyros, Bora will expand his pipelines by adding some candidates such as Vigafyde (vigabatrin), which is indicated for the treatment of infantile spasms.
Product Name : Vigafyde
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 25, 2024
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Bora Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pyros Pharmaceuticals: FDA Approves VIGAFYDE as Ready-to-Use Oral Solution
Details : Vigafyde (vigabatrin) is approved as monotherapy for pediatric patients with refractory complex partial seizures or infantile spasms in patients 1 month to 2 years of age.
Product Name : Vigafyde
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 17, 2024
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pyros Pharmaceuticals Reports Positive Outcome in European Procedure for VIGZIP™ Approval
Details : Vigzip (vigabatrin) is a Gamma-amino-N-butyrate transaminase inhibitor, which is indicated for the treatment of patients with infantile spasms (West's syndrome).
Product Name : Vigafyde
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2024
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Receives Final Approval from The USFDA for Vigabatrin for Oral Solution USP, 500 mg
Details : Vigabatrin its action as an irreversible inhibitor of γ-aminobutyric acid transaminase (GABA-T), the enzyme responsible for the metabolism of the inhibitory neurotransmitter GABA. This action results in increased levels of GABA in the central nervous sy...
Product Name : Sabril-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 03, 2023
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aurobindo Receives FDA Approval for Vigabatrin for Oral Solution USP, 500mg
Details : Aurobindo Pharma’s Vigabatrin for Oral Solution USP, 500 mg are an AB-rated generic equivalent to the reference listed drug (RLD), Sabril for Oral Solution of Lundbeck Pharmaceuticals, LLC.
Product Name : Vigabatrin-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 30, 2021
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Ethypharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
ORPHELIA, Ethypharm Sign Kigabeq® Licensing Deal for China
Details : Orphelia has granted Ethypharm exclusive rights under a license agreement to commercialize Kigabeq (vigabatrin) in China. Kigabeq is indicated as a first-line treatment for infantile spasms.
Product Name : Kigabeq
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 19, 2021
Lead Product(s) : Vigabatrin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Ethypharm
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
